GLPwatch
Byetta for Alcohol use disorder
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for alcohol use disorder, and any use for this condition is off-label or investigational. A randomized, placebo-controlled clinical trial has investigated exenatide once weekly for alcohol use disorder, and post hoc results examined its effect on biomarkers in individuals with the condition.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Alcohol use disorder |
| Approval status | Investigational / off-label |
| Research papers | 2 |
Byetta is not FDA-approved for alcohol use disorder; the research below reflects investigational or off-label study only.
Research on exenatide for alcohol use disorder (2)
- Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
- Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.